Drugs / ombipepimut-S
ombipepimut-S
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02498665 | Nov 2015 → Aug 2018 | acute myeloid leukemia, glioblastoma, malignant pancreatic neoplasm, melanoma +5 | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT02750891 | Apr 2016 → Jan 2020 | diffuse intrinsic pontine glioma, glioblastoma | Sumitomo Pharma Co., Ltd. | Completed | Missed primary |
| Phase 1/2 | NCT02436252 | May 2015 → Mar 2020 | myelodysplastic syndrome | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT03149003 | Dec 2017 → Aug 2021 | glioblastoma | Sumitomo Pharma America, Inc. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04747002 Comparator | Jun 2020 → Mar 2024 | acute myeloid leukemia | Osaka University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-12-15 | Sumitomo Pharma America, Inc. | Results Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888 in Patients with Glioblastoma Terminates sumitomo-pharma.com ↗
The second interim analysis was done at 185 events for evaluating OS and no new safety concerns were identified by the Independent Data Monitoring Committee (IDMC). |
| 2016-11-04 | Sumitomo Pharma America, Inc. | Results Sumitomo Dainippon Pharma announces the data of an investigational WT1 cancer peptide vaccine, DSP-7888 will be presented at the ASH 2016 sumitomo-pharma.com ↗
DSP-7888 was well-tolerated in MDS patients and dose-dependent toxicity was not observed except for ISR, although ISR was observed in all patients. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-15 | Sumitomo Pharma America, Inc. | Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888 in Patients with Glioblastoma Terminates sumitomo-pharma.com ↗ |
| 2016-11-04 | Sumitomo Pharma America, Inc. | Sumitomo Dainippon Pharma announces the data of an investigational WT1 cancer peptide vaccine, DSP-7888 will be presented at the ASH 2016 sumitomo-pharma.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ombipepimut-S | “DSP-7888 Dosing Emulsion, also known as ombipepimut-S (United States Adopted Name; International Nonproprietary Name: adegramotide/nelatimotide), is an investigational...” PMID 33939067 ↗ May 2021 |
| Known as | adegramotide/nelatimotide | “DSP-7888 Dosing Emulsion, also known as ombipepimut-S (United States Adopted Name; International Nonproprietary Name: adegramotide/nelatimotide), is an investigational...” PMID 33939067 ↗ May 2021 |
| Known as | DSP-7888 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02750891 ↗ |
| Modality | Vaccine | “investigational therapeutic cancer vaccine comprising two synthetic peptides” PMID 33939067 ↗ May 2021 |
| Route | Subcutaneous | “administered either intradermally (ID) or subcutaneously (SC)” PMID 33939067 ↗ May 2021 |
| Target | WT1 | “a Wilms' tumor gene 1 (WT1) peptide vaccine” PMID 42176363 ↗ May 2026 |